Original Research

Clobetasol Propionate Shampoo 0.05% Is Efficacious and Safe for Long-term Control of Scalp Psoriasis

Clobetasol propionate (CP) shampoo 0.05% is an efficacious and safe treatment for scalp psoriasis. The aim of this double-blind, randomized, placebo-controlled study was to determine if CP shampoo is suitable for long-term disease control. Participants with moderate to severe scalp psoriasis (global severity score [GSS] of 3 or 4 on a scale of 0 [clear] to 5 [very severe]) first received once daily CP shampoo treatment for up to 4 weeks. Responders were subsequently randomized to receive the CP shampoo or vehicle twice weekly maintenance regimen for up to 6 months. When relapse occurred (defined as GSS>2), participants resumed once daily CP shampoo treatment; when symptoms diminished (GSS≤2), they readopted the twice weekly maintenance regimen. At all visits significantly more participants treated with CP shampoo did not relapse compared with participants treated with vehicle (P<.001 only approximately one-third of participants treated with vehicle remained relapse free at month while this rate was observed months later after baseline maintenance phase in the cp shampoo group. group were still versus there no greater incidence skin atrophy telangiectasia or hypothalamic-pituitary-adrenal axis suppression compared clobetasol propionate is efficacious and safe for acute management long-term moderate to severe scalp psoriasis.>


 

Recommended Reading

TNF Blocker Risk-Benefit Analysis Proves Favorable
MDedge Dermatology
Ustekinumab Approved With Safety Requirement
MDedge Dermatology
Antiangiogenesis Offers New Tactic for Inflammatory Disease
MDedge Dermatology
Ustekinumab Found to Help Improve Sexual Function in Psoriasis Patients
MDedge Dermatology
IL-17A Blocker Shows Early Promise for Psoriasis
MDedge Dermatology
IVIG Guidelines Highlight Autoimmune Uses
MDedge Dermatology
UV Exposure May Be Tied to Dermatomyositis in Women
MDedge Dermatology
Drop Methotrexate At Week 12 in Poor Responders : Less than PASI-50 flags need for a biologic.
MDedge Dermatology
Belimumab Shows Efficacy in Second Lupus Trial
MDedge Dermatology
Anti-TNF Agents May Up Skin Cancer Risk
MDedge Dermatology